241 related articles for article (PubMed ID: 26408334)
1. A three-signal model of T-cell lymphoma pathogenesis.
Wilcox RA
Am J Hematol; 2016 Jan; 91(1):113-22. PubMed ID: 26408334
[TBL] [Abstract][Full Text] [Related]
2. Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?
Iqbal J; Wilcox R; Naushad H; Rohr J; Heavican TB; Wang C; Bouska A; Fu K; Chan WC; Vose JM
Blood Rev; 2016 Mar; 30(2):89-100. PubMed ID: 26319391
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Klemke CD; Goerdt S
G Ital Dermatol Venereol; 2008 Dec; 143(6):365-74. PubMed ID: 19169209
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin.
Wu X; Sells RE; Hwang ST
J Invest Dermatol; 2011 Aug; 131(8):1727-34. PubMed ID: 21490619
[TBL] [Abstract][Full Text] [Related]
5. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
[TBL] [Abstract][Full Text] [Related]
6. New drugs for aggressive B-cell and T-cell lymphomas.
Murawski N; Pfreundschuh M
Lancet Oncol; 2010 Nov; 11(11):1074-85. PubMed ID: 21051020
[TBL] [Abstract][Full Text] [Related]
7. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
Menter T; Tzankov A; Dirnhofer S
Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
[TBL] [Abstract][Full Text] [Related]
8. T-cell lymphoma: Microenvironment-related biomarkers.
Tse E; Kwong YL
Semin Cancer Biol; 2015 Oct; 34():46-51. PubMed ID: 26057207
[TBL] [Abstract][Full Text] [Related]
9. The number of responding CD4 T cells and the dose of antigen conjointly determine the TH1/TH2 phenotype by modulating B7/CD28 interactions.
Rudulier CD; McKinstry KK; Al-Yassin GA; Kroeger DR; Bretscher PA
J Immunol; 2014 Jun; 192(11):5140-50. PubMed ID: 24752446
[TBL] [Abstract][Full Text] [Related]
10. Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Tian YF; Ahn H; Schneider RS; Yang SN; Roman-Gonzalez L; Melnick AM; Cerchietti L; Singh A
Biomaterials; 2015 Dec; 73():110-9. PubMed ID: 26406451
[TBL] [Abstract][Full Text] [Related]
11. Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.
Laribi K; Alani M; Truong C; de Materre AB
Recent Pat Anticancer Drug Discov; 2018; 13(3):308-340. PubMed ID: 29769011
[TBL] [Abstract][Full Text] [Related]
12. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
13. AP-1 is involved in ICOS gene expression downstream of TCR/CD28 and cytokine receptor signaling.
Watanabe M; Nakajima S; Ohnuki K; Ogawa S; Yamashita M; Nakayama T; Murakami Y; Tanabe K; Abe R
Eur J Immunol; 2012 Jul; 42(7):1850-62. PubMed ID: 22585681
[TBL] [Abstract][Full Text] [Related]
14. The microenvironment in lymphomas--dissecting the complex crosstalk between tumor cells and 'by-stander' cells.
Rosenquist R; Davi F; Ghia P
Semin Cancer Biol; 2014 Feb; 24():1-2. PubMed ID: 24365642
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
Devata S; Wilcox RA
Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
[TBL] [Abstract][Full Text] [Related]
16. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
[TBL] [Abstract][Full Text] [Related]
17. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.
Baruah P; Lee M; Odutoye T; Williamson P; Hyde N; Kaski JC; Dumitriu IE
Immunobiology; 2012 Jul; 217(7):669-75. PubMed ID: 22204816
[TBL] [Abstract][Full Text] [Related]
18. T-cell lymphoma forum.
Kwong YL
Expert Rev Anticancer Ther; 2010 Apr; 10(4):493-8. PubMed ID: 20397914
[TBL] [Abstract][Full Text] [Related]
19. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
20. OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.
Jacquemin C; Schmitt N; Contin-Bordes C; Liu Y; Narayanan P; Seneschal J; Maurouard T; Dougall D; Davizon ES; Dumortier H; Douchet I; Raffray L; Richez C; Lazaro E; Duffau P; Truchetet ME; Khoryati L; Mercié P; Couzi L; Merville P; Schaeverbeke T; Viallard JF; Pellegrin JL; Moreau JF; Muller S; Zurawski S; Coffman RL; Pascual V; Ueno H; Blanco P
Immunity; 2015 Jun; 42(6):1159-70. PubMed ID: 26070486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
